Affichage 31 à 36 des 36 essais cliniques
1 | 2 | 3 | 4 |
ESSAIS CLINIQUES
    No essai
    ClinicalTrials.gov ID
Phase Coordonnateur(rice)
(EN) A Randomized Phase 3 Trial of Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
    COG-ANHL1931
    NCT04759586
     Actif en recrutement
CENTRE UNIVERSITAIRE DE SANTE MCGILL
HOPITAL DE MONTREAL POUR ENFANTS
Stephanie Badour
514-412-4400 poste 23807
(EN) A Multicenter, Open-label, Phase 2 Dose Escalation and Confirmation, and Efficacy Expansion Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP in Participants With DLBCL
    MK-2140-007 (waveLINE)
    NCT05406401
     Actif en recrutement
CIUSSS DU NORD-DE-L'ILE-DE-MONTREAL
HOPITAL DU SACRE-COEUR-DE-MONTREAL
Caroline Chagnon
514-338-2222 poste 2818
(EN) A Phase 1, Multicenter, Open-label, Dose Finding Study of CC-96673 in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
    CC-96673-NHL-001
    NCT04860466
     Actif en recrutement
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
(EN) A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies
    MK-2140-006
    NCT05458297
     Actif en recrutement
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
Edrian Gabrielle Bumanlag
514-840-8222 poste 23638
(EN) A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma
    GO40515
    NCT03677141
     Actif en recrutement
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
Aline Khayat
514-340-8222
(EN) A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas
    IGM-2323-001
    NCT04082936
     Actif en recrutement
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
Chadi Zakaria
514-340-8222 poste 28326
1 | 2 | 3 | 4 |